GlaxoSmithKline
🇬🇧United Kingdom
- Country
- 🇬🇧United Kingdom
- Ownership
- Public
- Established
- 1929-01-01
- Employees
- 70.2K
- Market Cap
- $90B
- Website
- http://www.gsk.com
- Introduction
GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the Commercial Operations, and Research and Development segments. The Commercial Operations segment has three product groups of specialty medicines, vaccines, and general medicines. The company was founded in 1715 and is headquartered in Middlesex, the United Kingdom.
Study Of Generalized Anxiety Disorder
Phase 2
Completed
- Conditions
- Anxiety DisorderAnxiety Disorders
- Interventions
- Drug: PlaceboDrug: Paroxetine
- First Posted Date
- 2005-08-26
- Last Posted Date
- 2011-01-31
- Lead Sponsor
- GlaxoSmithKline
- Registration Number
- NCT00135525
Study Of 323U66 SR In Major Depressive Disorder
Phase 2
Completed
- Conditions
- Depressive Disorder
- First Posted Date
- 2005-08-26
- Last Posted Date
- 2019-02-01
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 234
- Registration Number
- NCT00135512
- Locations
GSK Investigational Site
Hib-MenCY-TT Vaccine Study Compared to Licensed Hib and Meningococcal Serogroup C Conjugate Vaccines
Phase 2
Completed
- Conditions
- Haemophilus Influenzae Type bNeisseria Meningitidis
- Interventions
- Biological: MenHibrix (Hib-MenCY-TT)Biological: Infanrix® PentaBiological: Prevenar®Biological: ActHIB®Biological: M-M-R®IIBiological: Varivax®Biological: Meningitec®Biological: PedvaxHIB®
- First Posted Date
- 2005-08-25
- Last Posted Date
- 2018-07-19
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 1104
- Registration Number
- NCT00134719
- Locations
- 🇦🇺
GSK Investigational Site, Perth, Western Australia, Australia
Study of 2 Doses of Oral Live Attenuated Human Rotavirus (HRV) Vaccine for the Prophylaxis of Rotavirus Gastroenteritis
Phase 3
Completed
- Conditions
- Infections, Rotavirus
- First Posted Date
- 2005-08-25
- Last Posted Date
- 2016-09-23
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 150
- Registration Number
- NCT00134732
- Locations
- 🇰🇷
GSK Investigational Site, Seoul, Korea, Republic of
A Single Dose Of Compound SB-681323 Compared To Prednisolone On A Protein That Is an Indicator For Rheumatoid Arthritis
Phase 2
Completed
- Conditions
- Arthritis, Rheumatoid
- First Posted Date
- 2005-08-25
- Last Posted Date
- 2017-07-31
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 77
- Registration Number
- NCT00134693
- Locations
- 🇬🇧
GSK Investigational Site, Sheffield, United Kingdom
Topical SB-275833 Ointment, 1% For The Treatment Of Impetigo
Phase 3
Completed
- Conditions
- Skin Infections, Bacterial
- First Posted Date
- 2005-08-24
- Last Posted Date
- 2017-01-23
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 520
- Registration Number
- NCT00133874
- Locations
- 🇿🇦
GSK Investigational Site, Pretoria, South Africa
Treatment Of Impetigo With Topical SB-275833 Ointment, 1% Versus Topical Placebo Ointment
Phase 3
Completed
- Conditions
- Impetigo
- First Posted Date
- 2005-08-24
- Last Posted Date
- 2016-09-23
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 210
- Registration Number
- NCT00133848
- Locations
- 🇵🇪
GSK Investigational Site, Lima, Peru
3 Formulations of Hib-MenCY-TT Vaccine & 1 Formulation of Hib-MenC-TT Vaccine Compared to Licensed Meningococcal Serogroup C Conjugate Vaccine, Each Administered at 2,3,4 Mths of Age
Phase 2
Completed
- Conditions
- Haemophilus Influenzae Type bNeisseria Meningitidis
- Interventions
- Biological: Hib-MenCY-TT vaccineBiological: Hib-MenC-TT vaccineBiological: Menjugate ®Biological: Infanrix penta ®Biological: Infanrix hexa ®
- First Posted Date
- 2005-08-11
- Last Posted Date
- 2018-08-27
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 388
- Registration Number
- NCT00129116
- Locations
- 🇩🇪
GSK Investigational Site, Hamburg, Germany
Comparison of GSKBiologicals' Hib-MenCY-TT Vaccine vs Licensed Hib Conjugate or Meningococcal Vaccine
Phase 2
Completed
- Conditions
- Haemophilus Influenzae Type bNeisseria Meningitidis
- Interventions
- Biological: GSK Biologicals' Haemophilus influenza type b and Neisseria meningitidis serogroups C and Y-tetanus toxoid conjugate vaccine 792014 vaccineBiological: PediarixBiological: ActHIBBiological: MenomuneBiological: Prevnar
- First Posted Date
- 2005-08-11
- Last Posted Date
- 2018-08-24
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 756
- Registration Number
- NCT00129129
- Locations
- 🇺🇸
GSK Investigational Site, Warwick, Rhode Island, United States
Vaccine To Prevent Cervical Intraepithelial Neoplasia or Cervical Cancer in Younger Healthy Participants
Phase 3
Completed
- Conditions
- Cervical CancerPrecancerous Condition
- Interventions
- Biological: hepatitis A inactivated virus vaccineBiological: human papillomavirus 16/18 L1 virus-like particle/AS04 vaccine
- First Posted Date
- 2005-08-10
- Last Posted Date
- 2019-03-08
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 7466
- Registration Number
- NCT00128661
- Locations
- 🇨🇷
Proyecto Epidemiologico Guanacaste, Liberia, Costa Rica
© Copyright 2025. All Rights Reserved by MedPath